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The ﬁrst objective was to investigate new bone formation in a critical-size metaphyseal defect in the
femur of ovariectomized rats ﬁlled with a strontium modiﬁed calcium phosphate cement (SrCPC)
compared to calcium phosphate cement (CPC) and empty defects. Second, detection of strontium release
from the materials as well as calcium and collagen mass distribution in the fracture defect should be
targeted by time of ﬂight secondary ion mass spectrometry (TOF-SIMS). 45 female SpragueeDawley rats
were randomly assigned to three different treatment groups: (1) SrCPC (n ¼ 15), (2) CPC (n ¼ 15), and (3)
empty defect (n ¼ 15). Bilateral ovariectomy was performed and three months after multi-deﬁcient diet,
the left femur of all animals underwent a 4 mm wedge-shaped metaphyseal osteotomy that was
internally ﬁxed with a T-shaped plate. The defect was then either ﬁlled with SrCPC or CPC or was left
empty. After 6 weeks, histomorphometric analysis showed a statistically signiﬁcant increase in bone
formation of SrCPC compared to CPC (p ¼ 0.005) and the empty defect (p ¼ 0.002) in the former fracture
defect zone. Furthermore, there was a statistically signiﬁcant higher bone formation at the tissueeim-
plant interface in the SrCPC group compared to the CPC group (p < 0.0001). These data were conﬁrmed
by immunohistochemistry revealing an increase in bone-morphogenic protein 2, osteocalcin and
osteoprotegerin expression and a statistically signiﬁcant higher gene expression of alkaline phosphatase,
collagen10a1 and osteocalcin in the SrCPC group compared to CPC. TOF-SIMS analysis showed a high
release of Sr from the SrCPC into the interface region in this area compared to CPC suggesting that
improved bone formation is attributable to the released Sr from the SrCPC.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
The treatment of osteoporotic fractures and particularly of
osteoporotic fractures with bone defects remains a criticaldic Trauma Surgery, Justus-
35385 Giessen, Germany.
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Ltd. Open access under CC BY-NC-ND licenchallenge. Biomaterials with the potential to stimulate bone heal-
ing have gained interest to improve healing and the treatment
outcome for patients with osteoporotic fractures [1]. Injectable
calcium phosphate cements have been used in bone surgery since
many years based on their osteoconductive properties to stimulate
new bone formation [2]. Strontium (II) (Sr2þ) has been shown to
effectively both stimulate bone formation and inhibit osteoclastic
activity and has been introduced into all day clinical practice as oral
strontium ranelate medication against osteoporosis [3,4]. Local
administration of strontium mainly from functionalized titanium
implant surfaces [5e10] or from strontium-substituted hydroxy-
apatite coatings [11,12] gained interest due to the positive effects of
strontium on new bone formation for better implant ﬁxation.se. 
U. Thormann et al. / Biomaterials 34 (2013) 8589e85988590We recently showed the possibility to generate a strontium (II)
modiﬁed calcium a-tricalcium phosphate based phosphate cement
(SrCPC) in which the CaCO3 portion in the precursor mixture is
replaced completely with strontium carbonate (SrCO3, 99.994%),
resulting in Sr/Ca ratio of 0.123 [13]. The intention of this recently
developed composite material is to use the osteoconductive cal-
cium phosphate cement as a drug carrier for the local release of
strontium into bone defects in order to leverage the osteoanabolic
and anti-osteoclastic activity not in a systemic but local environ-
ment to achieve high strontium concentrations with subsequent
enhancement of new bone formation.
In vivo evaluation of SrCPC effects on new bone formation in
osteoporotic bone requires a clinically relevant animal model that
mimics osteoporotic fractures. Recently, we published a rat model
with a critical size defect in the distal metaphyseal femur in which
biomaterials can be tested [14]. This model shows important
reduction in bone mineral density (BMD) of both spine and femur
after bilateral ovariectomy and special diet deﬁcient in calcium,
phosphorus and vitamin D3-, soy- and phytoestrogen-free
compared to sham animals. The osteotomy addresses the meta-
physeal region of the distal femur respecting the fact that mainly
metaphyseal regions are affected by osteoporotic fractures and uses
the clinically relevant surgical technique of plate ﬁxation of such a
fracture defect.
Time of ﬂight secondary ion mass spectrometry (TOF-SIMS)
originates from materials science with increasing applications in
life science due to its ability to assess chemical composition of solid
surfaces down to about 100 nm lateral resolution [15,16]. In brief, a
high energetic cluster ion beam is scanning over the sample surface
in order to release molecules, atoms and ions that subsequently ﬂy
away from the sample surface due to the ion impact. The ions can
then be collected by an electrical ﬁeld and are analyzed in a time of
ﬂight analyzer by their mass to charge ratio which enables to
visualize strontium and calcium distribution in bone.
The ﬁrst intention of this study was to evaluate the effects on
new bone formation of strontium modiﬁed calcium phosphate
cement (SrCPC) compared to a strontium free calcium phosphate
cement of otherwise similar composition (CPC) and an empty
defect control group with the use of the above mentioned clinically
relevant rat model [14]. The second intention was to use TOF-SIMS
technology to detect strontium release from thematerials as well as
calcium and collagen mass distribution in the defect area.
2. Materials and methods
2.1. Study design and general information
All interventions were performed in full compliance with the institutional and
German protection laws and approved by the local animal welfare committee
(Reference number: V 54 e 19 c 20-15 (1) GI 20/28 Nr. 108/2011). 45 female Spra-
gueeDawley rats were randomly assigned to three different treatment groups: (1)
strontium modiﬁed calcium phosphate (SrCPC) (n ¼ 15), (2) calcium phosphate
cement (CPC) (n ¼ 15), and (3) empty defect control (n ¼ 15). The animals under-
went induction of osteopenic bone status by bilateral ovariectomy combined with a
multi-deﬁcient diet as previously described [14,17,18]. Three months after ovariec-
tomy and multi-deﬁcient diet, a 4 mm defect in the distal femur metaphysis was
created that was stabilized with a mini-plate. The defect was subsequently ﬁlled
either with SrCPC, CPC or left empty (Fig. 1). The femurs were harvested after 6
weeks and histomorphometrical assessment including immunohistochemistry,
enzyme histochemistry, molecular-biological analysis and TOF-SIMS analysis for
detection of strontium, calcium and collagen was performed.
2.2. Calcium phosphate cement (CPC) and strontium (II)-modiﬁed calcium
phosphate cement (SrCPC)
Calcium phosphate cement (CPC) as well as a strontium (II)-modiﬁed cement
(SrCPC) were used in this study. Synthesis and material properties have been
described recently in detail elsewhere [13]. In brief, CPC precursor was composed of
a-tricalcium phosphate (a-TCP; a-Ca3(PO4)2), calcium hydrogenphosphate
(CaHPO4), calcium carbonate (CaCO3) and hydroxyapatite (Ca10(PO4)6(OH)2) as ﬁrstdescribed by Driessens and co-workers [19]. In case of strontium-containing SrCPC,
CaCO3 was replaced completely with strontium carbonate (SrCO3, 99.994%, Alfa
Aesar, Karlsruhe, Germany), resulting in the formation of a Sr2þ-substituted apatite
cement matrix with a Sr/Ca ratio of 0.123. Cement precursor powders were supplied
by InnoTERE GmbH (Radebeul, Germany) and were sterilized by g-radiation at
25 kGy. Prior to implantation, cement powder was manually mixed with 4 wt.%
aqueous Na2HPO4 solution using a liquid-to-powder-ratio of 0.40 and 0.35 ml/g for
CPC and SrCPC, respectively.
2.3. Animals and surgical procedure
10 weeks old healthy female SpragueeDawley rats were purchased from Charles
River (Sulzfeld, Germany), with an initial weight of 250e290 g. All animals were
randomly assigned to the three treatment groups. Animals underwent an acclima-
tization period of fourweeks before induction of osteopenic bone status as described
previously [17,18]. Brieﬂy, rats were ovariectomized bilaterally with a dorsal
approach. Thereafter, the animals received a low calcium-, phosphorus- and vitamin
D3-, and soy- and phytoestrogen-free multi-deﬁcient diet (Altromin-C1034, Altro-
min Spezialfutter GmbH, Lage, Germany), for 12 weeks.
Awedge-shaped osteotomy was performed on the distal end of the left femur as
previously described [14]. In brief, the distal femur was ﬁxed laterally with 7-hole
T-shaped mini-plate (Leibinger XS-mini-plate, Stryker, Schökirchen, Germany).
Then the osteotomy at the distal metaphyseal area with creation of a wedge-shaped
defect with a lateral length of 4 mm and a medial gap of 0.35 mm using an ultra-
sound bone saw (Piezosurgery 3, Saw blade OT7S-3, Mectron, Köln, Germany) was
performed. The defect was then treated according to the study protocol and the
animals either received SrCPC, CPC or no biomaterial (Fig. 1). Postoperatively, ani-
mals continued receiving the deﬁcient diet until euthanized at 6 weeks post femur
surgery. Animals were euthanized under inhalation of CO2 after general anesthesia.
2.4. End-point and specimen preparation
Animals were euthanized 6weeks post femur surgery. The left femorawere then
harvested, and all surrounding soft-tissue was removed. Only samples with intact
ﬁxation plates were used for further analysis.
2.5. TOF-SIMS
Measurements were done with a TOF-SIMS 5e100 machine (IONTOF, Münster,
Germany) on Technovit section (see chapter “Histological analysis”). The machine is
equipped with a 25 keV Bi-cluster ion gun for surface analysis. The maximum
dimension for the primary ion raster mode is 500  500 mm2. For survey images, so
called stage scans, were used. Single ion images of 300  300 mm2 were merged to a
big mass image of 7.0  14.5 mm2 for the empty defect, 6.7  14.2 mm2 for CPC and
8.113.6 mm2 for the SrCPC group.With a pixel density of 100/mm, the primary ion
gun runs in the high current bunched (hc-bu) mode with highest mass resolution
and a lateral resolution of about 10 mm for this large survey images. For more
detailed images, the low current bunched (lc-bu) mode with a lateral resolution of
2 mmwas used. The pixel density was 1000/mm and single frames of 300 300 mm2
were assembled to survey images of 1.8  0.9 mm2. As primary ion species Bi3þwas
used. Data evaluationwas done with the Surface Lab 6.3 software (IONTOF, Münster,
Germany) delivering detailed mass maps of the analyzed surface. In one mass image
usually only the distribution of one selected mass is shown. Within this image,
bright and dark pixels represent a high and low count rate of this mass, respectively.
For more detailed information about this method the reader is referred to the
literature [16].
Mass distribution analysis of Srþ, Caþ, and of C4H8Nþ which was shown to
correlate with collagen I [20] was performed. Furthermore, an overlay image of the
collagen and Ca signal was depicted.
2.6. Histological analysis and histomorphometry
For histological analysis, the harvested femurs were ﬁxed in phosphate- buff-
ered 4% paraformaldehyde and stored at 4 C until processing. Samples were then
embedded in Technovit 9100 NEU according to the manufacturers protocol (Her-
aeus Kulzer, Hanau, Germany). After embedding, Technovit blocks were sectioned
into 5 mm thick slices with the aid of Kawamoto’s ﬁlm (Section-Lab Co. Ltd., Japan) to
keep the biomaterials intact. For histological and histomorphometrical analysis
these sections were stained with movat-pentachrome as described earlier [21].
Two regions of interest (ROIs) were used for histomorphometric evaluations
(Fig. 2). The ﬁrst ROI was made by directly tracing over the material followed by a
100 pixels increase to include the biomaterialetissue interface. The second ROI
comprised the entire initial wedge-shaped osteotomized defect area to assess the
new bone formation within the former fracture defect area. With the help of Adobe
Photoshop CS6, themeasurements for area of bone, ROIs, implant, and the voidwere
made respectively to determine bone versus tissue ratio (BV/TV). A count for
tartrate-resistant acid phosphatase (TRAP) positive cells was also performed. The
consecutive sections were then used for all described methods. The measurements
were done blind folded with regards to the test groups.
Fig. 1. Intraoperative appearance of the distal femur of the empty defect (A), defect ﬁlled with SrCPC (B) or CPC (C) stabilized with a T-shape mini-plate.
U. Thormann et al. / Biomaterials 34 (2013) 8589e8598 85912.7. Immunohistochemistry
Immunohistochemistry was carried out with the following antibodies: Rabbit
Anti-BMP2 Polyclonal Antibody (AP20597PU-N; Acris, Herford, Germany), Rabbit
Anti-Osteoprotegerin Polyclonal Antibody (250800; Abbiotec, San Diego, CA, USA),Fig. 2. Schematic diagram of a movat-pentachrome staining of undecalciﬁed technovit sec
uation: First ROI (within black outline) was used to evaluate the new bone formation at the
the entire defect region to examine the new bone formation in the initial fracture defect (BRabbit Anti CD254/RANKL Polyclonal Antibody (AP30826PU-N; Acris, Herford,
Germany), Rabbit Anti CD31 Antibody (250590; Abbiotec, San Diego, CA, USA).
Goat Anti-Rabbit (BA-1000, Vector) was used as a secondary antibody followed by
a Vectastain ABC kit (Elite PK-6100, Standard, Vector Laboratories, Burlingame, CA,
USA). Finally visualization was done using Nova Red (SK4800, Vector Laboratories,tions with the two regions of interest (ROIs) for quantitative histomorphometric eval-
tissue-implant interface (A). The second ROI (enclosed within black outline) comprises
). Speciﬁc regions are labeled as follows: b, bone; m, material; sc, screw.
U. Thormann et al. / Biomaterials 34 (2013) 8589e85988592Burlingame, CA, USA) and hematoxylin (Shandon Inc., Pittburgh, USA) was used as a
counterstain.
2.8. Enzymehistochemical analysis
TRAP staining was used to investigate the osteoclast activity. After deplastiﬁca-
tion, the samples were treated with sodium acetate buffer and incubated in Napthol-
AS-TR phosphate (N6125-1G, Sigma, Germany) in NeN-Dimethyl formamide (Sigma
Aldrich) and sodium tartrate (Merck, Germany) with Fast Red TR salt (Sigma Aldrich)
at 37 C for 1 h. This was followed by counterstaining with hematoxylin (Shandon
Inc., Pittsburgh). TRAP-positive cells were analyzed in both the ROI’s.
Images were taken using Axioplan 2 Imaging system (Carl Zeiss, Germany) with
a Leica DC500 camera (Leica, Bensheim, Germany), acquired with Leica IM1000
software and processed using Adobe photoshop CS6.
2.9. mRNA preparation and gene analysis
Left femora obtained 6weeks after operationwere snap frozen in RNAlater RNA
Stabilization Solution (Ambion, CA, USA) and stored at80 C until RNA isolation for
expression analysis of the following target genes for new bone formation:
1. Alkaline phosphatase (ALP) as an osteoblast marker indicating mineralization
of bone; 2. Osteocalcin (OCN) as a noncollagenous protein secreted by osteoblasts
which plays a role in mineralization and calcium ion homeostasis; 3. Collagen type
10 alpha1 (Col10a1) as a hypertrophic chondrocytes marker; 4. Runt-related tran-
scription factor 2 (Runx2) as essential protein for osteoblastic differentiation; 5.
Collagen type I alpha1 as major component of type I collagen, (Col1a1).
The following target genes were analyzed for osteoclast processes: 1. TNFSF11
gene (RANKL, RANK ligand as a member of the tumor necrosis factor (TNF) cytokine
family, which is a ligand for osteoprotegerin and functions as a key factor for oste-
oclast differentiation and activation) 2. TNFRSF11B gene (osteoprotegerin; OPG; as
decoy receptor for RANKL and thereby neutralizing its function in osteoclasto-
genesis) 3. carbonic anhydrase as an osteoclasts marker involved in bone matrix
dissolution.
b2-microglobulin (B2M) was used as a reference gene. Primer sequences are
provided in the Supplemental Table 1.
RNA isolation was done from the entire defect region from each sample using
Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. RNA quality and quantity was measured using Nanodrop2000 (Thermo
scientiﬁc, Schwerte, Germany) and Qubit 2.0 ﬂuorometer (Invitrogen, Darmstadt,
Germany). 0.5 mg of RNA was reverse-transcribed to cDNA with the Quantitect Kit
(Qiagen, Hilden, Germany) as described in the manufacturer’s protocol. Primers
were designed to amplify 72e191 bp long amplicons within the coding sequences of
the above described target genes.
Quantitative polymerase chain reaction (qPCR) analysis was performed using
the LightCycler detection system (Roche, Mannheim, Germany) in combinationwith
the Quantifast SYBR Green PCR Mastermix (Qiagen, Hilden, Germany) for Runx2-,
ALPL-, OCN-, Col1a1-, Col10a1-, RANKL- and OPG-primers and B2M reference gene-
primers. Roche LightCycler Kit was used for Car2-primers and B2M- reference
gene-primers. For RT-PCR, 1 ml cDNA, 5 ml Quantifast SYBR Green PCR Mastermix or
2 ml Roche 5 PCR Mastermix and 0.1 ml of each primer (20 mM) were supplemented
with RNase free H2O to a ﬁnal volume of 10 ml.
The thermal cycling programwith Quantifast Mastermix comprised one initial
denaturation step of 5 min at 95 C, followed by 40 cycles of 10 s at 95 C and 30 s at
60 C. Finally, a melting curve was performed to verify the product’s speciﬁcity and
identity.
qPCR analysis using Roche PCRMastermix implemented an initial denaturation
step of 10 min at 95 C followed by a cycling protocol which included a denaturation
step at 95 C for 5 s and an annealing step at 60 C for 5 s followed by a ﬁnal
extension at 72 C for 5 s carried out for 40 cycles. Amelting curve analysis was done
to determine the product speciﬁcity. All analyses were done in duplicate and the
means were used for further calculations. The following controls were performed:
every sample processed without reverse transcription (RT) to control for
contamination with genomic DNA and RT-PCR runs without template (H2O). Spec-
iﬁcity of ampliﬁcation was conﬁrmed by melting curve analyses and 2% agarose gel
electrophoresis.
The ampliﬁcation efﬁciency for the tested primer pairs varied from 1.93 to 2.00
which are the expected values for compared genes. The relative gene expression
ratio for each gene was calculated using the REST method based on the PCR efﬁ-
ciency (E) and Ct of a sample compared with the control, and expressed in com-
parison to the reference gene, according to Pfafﬂ’s mathematical model:
Ratio ¼ (Etarget) DCt target (control-sample)/(Eref) DCt ref (control-sample) [22].
2.10. Statistical analysis
Histomorphometric results are presented as mean  standard error of the mean
(SEM) with minimum and maximum values [mean  SEM; min.: maximum] and
analyzed using the Statistical Package PASW 21.0 (SPSS Inc., USA). Data were not
found normally distributed and ManneWhitney U unpaired nonparametric data
with bonferroni correction. Expression analysis is presented as box plots and wereanalyzed using REST method. P-values of less than 0.05 were chosen to indicate
signiﬁcance.
3. Results
3.1. Clinical observations
39 of the 45 animals survived the entire observation periodwhich
represented 11 animals of the control,15 animals of the SrCPC and 13
animals of the CPC group. In these animals clinical healing of the
surgical wounds and recovery of mobility of the animals progressed
uneventfully with no visible adverse effects in all groups until the
end of the observation period of 6 weeks post femur surgery. Three
animals were lost during anesthesia, one animal died directly after
ovariectomy and two other rats after femur surgery.
At the time of femur harvesting, plate breakage was noted in 2 of
the remaining11animals in thecontrolgroup, in4of15animals of the
SrCPC and in7 of 13 animals in theCPCgroupwithout any statistically
signiﬁcant differences between the groups (empty defect vs. CPC:
p ¼ 0.58; empty defect vs. SrCPC: p ¼ 0.61; SrCPC vs. CPC: p ¼ 0.06).
3.2. TOF-SIMS analysis
Visualization of strontium distribution by TOF-SIMS was
possible in all three groups (Fig. 3). The evaluation of the strontium
distribution of the empty defect shows that there is a natural Sr
background count rate of about 11 counts while CPC implants were
found to exhibit a mean Sr count rate of 24 counts. The highest Sr
count rate of about 3000 counts was obtained in the center region
of the Sr2þmodiﬁed SrCPC implant. Therewere count rates of about
80 counts in the biomaterialetissue interface in a distance up to
1 mm to the biomaterial with a Sr concentration gradient to all
sides of the implant. The Sr content decreased with increasing
distance from the implant. In a distance of up to 6 mm to the
implant, an increased Sr concentration could still be detected.
Ca could be found in cortical bone in all three groups and in the
CPC and SrCPC material itself. In all specimens bone marrow areas
were almost free of Ca signals. Within the region of newly formed
bone in the interface region, Sr and Ca were in the same area as the
collagen signal.
3.3. Histomorphometry
Histomorphometric analysis showed a statistically signiﬁcant
increase in the bone formation for the CPC [0.042 0.03; 0.01:0.09]
(p ¼ 0.01) and the SrCPC [0.11  0.01; 0.1:0.15] (p ¼ 0.002) treat-
ment group compared to the empty defect [0.004  0.002;
0.0:0.01] in the former fracture defect zone (Fig. 4A). SrCPC treated
animals showed a statistically higher new bone formation in rela-
tion to the defect areas ﬁlled with CPC (0 ¼ 0.005).
Furthermore, there was more bone formation at the bone-
biomaterial interface region for the SrCPC [47.5  13.8; 29.5:64.5]
compared to CPC [6.4  1.5; 4.9:8.2] which was also statistically
signiﬁcant (p < 0.0001) (Fig. 4B).
TRAP-positive cells were also found to be signiﬁcantly higher in
the SrCPC group [87.5 21.9; 43:100] in comparison to the CPC group
[CPC: 43.7  2.6; 40:46] (p ¼ 0.033) and the empty defect control
group [30.6  2.5; 26:33] (p ¼ 0.005) (Fig. 5). Most of the TRAP-
positive cellswere found inat thebiomaterialetissue interfaceregion.
3.4. Histology
The animals of the SrCPC and the CPC group showed the
implanted biomaterial in the correct position where the wedge-
shaped defects were created initially at the distal metaphyseal
Fig. 3. Overview of movat-pentachrome stained sections of representative specimens of the empty defect (A), CPC (B) and SrCPC group (C) used for TOF-SIMS analysis. The small images under the overview images show mass
distribution of Caþ (upper left), Srþ (upper right), C4H8Nþ (lower right) and an overlay image of the Caþ and of the C4H8Nþ signal (lower left). For better distribution analysis of Srþ, the local count rates of Srþ are plotted versus the y-
axis and placed over the Sr-images.
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Fig. 4. Histomorphometrical analysis of new bone formation of SrCPC, CPC and empty control group in the initial fracture defect zone (A) and at the tissueebiomaterial interface (B).
Asterisks indicate (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001, respectively.
U. Thormann et al. / Biomaterials 34 (2013) 8589e85988594femur region (Fig. 6 B,C). Fragmentation of thematerial was seen in 5
of 7 animals in the SrCPC group. In all these animals, the fragmented
biomaterial was surrounded by osteoid, cartilage and ﬁbrous tissue
at the interface region. In the CPC group only 2 out of 7 animals
showed fragmentation of the material of which one had only very
little fragmentation and was surrounded mostly by ﬁbrous tissue.
Unmineralized osteoid was the most common tissue type found
in the defect region in the SrCPC group, mainly in vicinity of the
biomaterial and on the medial aspect of the distal femur. The
CPC group showed comparatively less osteoid formation and the
empty group almost lacked of osteoid in the initial defect area.
Furthermore, mainly bone and cartilage tissue with hypertrophic
chondrocytes were found in the SrCPC group in the defect region
surrounding the biomaterial (Fig. 6E). In the animals of the CPC
group mainly cell dense ﬁbrous tissue and proliferating chon-
drocytes were the predominant types (Fig. 6D). There was notice-
ably less cartilage formation in the empty defect control group
compared to the other two groups. In context to the medial side ofFig. 5. Macrophage count based on tartarate resistance acid phosphatase (TRAP) staining
fracture defect zone (A) and at the tissueebiomaterial interface (B). The asterisks indicate
tologically stained sections with TRAP showing an elevated distribution of red stained ce
interpretation of the references to color in this ﬁgure legend, the reader is referred to thethe osteotomy (apex of the wedge-shaped defect), the gap was
ﬁlled with cartilage and connective tissue in the SrCPC group
whereas in the CPC group, and to a greater extent in the control
group, large shifting of the cortical bones were seen. This space was
predominantly occupied with ﬁbrous tissue.
3.5. Immunohistochemical analysis
Immunohistochemical staining revealed a strong positive
BMP2 expression in the SrCPC group mainly in direct vicinity of
the biomaterial towards the biomaterial-metaphyseal cancelous
(distal) bone and mid cortical regions. An almost negligible
expressionwas seen in CPC and in the control group (Fig. 7)AeC. An
increased expression of OPG and OCN was also seen at the distal
and mid cortical region of the fracture gap in the SrCPC group
compared to the two other groups (Fig. 7)DeI. Furthermore, a
simultaneous reduction in the RANKL expression was detected in
the SrCPC group.over trabecular area (Ma/Tb.Ar) of SrCPC, CPC and empty control groups in the initial
(*) p < 0.05, (**) p < 0.01 and (***) p < 0.001 respectively. Photomicrographs of his-
lls in SrCPC group (E) when compared to CPC (D) and (E) empty control group (For
web version of this article.).
Fig. 6. Movat-pentachrome photomicrographs showing overview of histological sections of empty defect (A), CPC (B) and SrCPC (C). Enlarged images at the biomaterial interface
depicting large amounts of ﬁbrous connective tissue and proliferating chondrocytes in the CPC group (D) in contrast to new bone formation with large amounts of cartilage and
osteoid in the SrCPC group (E). The hypertrophic chondrocytes were the most abundant. Speciﬁc regions are labeled as follows: b, bone; c, cartilage; m, material; sc, screw; *
indicates material in the soft-tissue; arrow indicating the osteoid formation.
U. Thormann et al. / Biomaterials 34 (2013) 8589e8598 8595The analysis of new blood vessel formation using CD31 antibody
revealed a comparatively higher number of positively stained
vessels in the SrCPC group in comparison to the CPC group. An
increased positive reaction was seen with an increase in the
biomaterial fragmentation (SrCPC) thereby leading to an increase in
the granulation tissue and thus leading to an increased vessel for-
mation. Based on this principle, the empty defect which was ﬁlled
predominantly with the granulation tissue, showed a compara-
tively higher CD31 expression (Fig. 7JeL).
3.6. Molecular biology
The expression of several genes was determined by qPCR. Re-
sults showed expression differences between the CPC and SrCPC
groups normalized to B2M gene expression (Fig. 8). Expression of
ALP as an osteoblast marker indicating mineralization of bone was
higher in the SrCPC group when compared to the CPC group
(p ¼ 0.027). Osteocalcin expression analysis indicates a higher
osteocalcin expression in the SrCPC group when compared to theCPC group (p  0.001). Expression of Col X in SrCPC was signiﬁ-
cantly higher than that of the CPC (p ¼ 0.03) (Fig. 8A). Runx2 and
Col1a1 expression analysis showed no signiﬁcant difference be-
tween the SrCPC and the CPC group.
RANKL expression analysis revealed no signiﬁcant difference
between the two experimental groups. Expression levels of OPG
were not signiﬁcantly different between the groups. Moreover,
carbonic anhydrase is an osteoclast marker involved in bonematrix
dissolution, was not found to be signiﬁcantly expressed either
(Fig. 8B).
4. Discussion
The intention of this study was to investigate the in vivo effects of
a strontium modiﬁed calcium phosphate cement in a critical size
defect in the metaphyseal area of the distal femur in ovariectomized
rats. Both CPC and SrCPC revealed a statistically signiﬁcantly
enhanced new bone formation compared to the empty defect in the
defect region. It could be shown that the SrCPC treated animals
Fig. 7. Immunohistochemistry on undecalciﬁed technovit sections showing an increased expression of biomarkers involved in bone formation in SrCPC group. Increased expression
of BMP2 (C); OPG (F); osteocalcin (I); CD31 (L) was seen at the tissue implant interface in the SrCPC group in comparison to the CPC (B, E, H, K) and empty control group (A, D, G, J). *
indicates the biomaterial in the defect region of SrCPC and CPC group.
U. Thormann et al. / Biomaterials 34 (2013) 8589e85988596exhibited a statistically signiﬁcant higher new bone formation both
at the biomaterialebone interface and in the entire fracture defect
area compared to CPC suggesting that the local release of Sr from
SrCPC is able to positively inﬂuence osteogenesis. Immunohisto-
logical and molecular-biological investigations could conﬁrm the
enhanced new bone formation activities in the SrCPC group with
enhanced expression of BMP2, osteocalcin and OPG compared to CPC
and the empty defect control group. High CD31 expression suggests
concomitant new blood vessel formation in the SrCPC group.
These ﬁnding are in line with better new bone formation and
implant-bone contact of other in vivo studies on strontium-substituted hydroxyapatite coatings [11] or strontium-doped hy-
droxyapatite bone graft extender [23]. Recently, Andersen et al.
showed that the local delivery of strontium from surface func-
tionalized titanium implants could enhance bone-to-implant con-
tact for implants in the femoral shaft of healthy female Wistar rats
[5]. The authors concluded that strontium can be released into the
local milieu of osseointegrating implants to accelerate bone
ingrowth into the implant surface. However, all previous works did
not analyze the in vivo release of Sr into the bone which could be
done in our study with the help of TOF-SIMS. By this means, the
high Sr concentration in the interface region of the SrCPC implant
Fig. 8. Relative gene expression analysis between SrCPC and CPC. Alkaline phosphatase (ALP), Runt-related transcription factor 2 (Runx2), collagen type X alpha1 (Col10a1),
osteocalcin (OCN) as bone formation markers (A). RANKL, osteoprotegerin (OPG) and carbonic anhydrase as degradation markers (B). b2-microglobulin (B2M) was used as a
reference gene. The asterisks indicate (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001 respectively.
U. Thormann et al. / Biomaterials 34 (2013) 8589e8598 8597was clearly demonstrated. This ﬁnding allows to conclude that the
released Sr of the SrCPC cement is most likely to be responsible for
higher new bone formation compared to the CPC group. This can be
regarded as proof of principle that the local delivery of strontium
from Sr-modiﬁed/loaded implants or biomaterials is possible and
that strontium’s biological activity to stimulate new bone forma-
tion is preserved within the CPC.
Ni et al. reported about the detection of Sr, Ca and further ele-
ments of a Sr-doped hydroxyapatite cement that was implanted
into the proximal femoral intramedullary canal for 6 months by
EDX and TOF-SIMS. However, therewas only amaximum count rate
for Sr of 3 in the 70 mm thick hydroxyapatite interface layer. In
contrast to this study, we found a high release of Sr up to a distance
of 5 mm to the implant. Sr, Ca and the collagen signal were found in
the same areas of the newly formed bone suggesting that the
released Sr from SrCPC was incorporated into the new bone.
The strontium modiﬁed calcium phosphate bone cement used
in the present study has been developed recently by complete
substitution of the CaCO3 portion in the precursor mixture of a
well-established, a-TCP based cement by SrCO3. This simple
approach which has been described in detail recently leads to a
cement which releases strontium ions in relevant dosages in vitro
[13]. A comparison of the in vitro strontium release and between
the ﬁndings of the current animal trial is difﬁcult. However, this
in vivo study can demonstrate that a considerable amount of
strontium is released from the SrCPC into the interface region and
into the surrounding tissue which is most likely related to
enhanced bone formation conﬁrming the in vitro ﬁndings that
biologically active doses of strontium can be released from SrCPC.
Regarding the in vivo degradation behavior of the materials,
more and better fragmentation of the SrCPC compared to the CPC
was found. This was associatedwith a statistically signiﬁcant higher
number of multinuclear cells in the SrCPC. With the assumption
that at least some multinuclear cells are osteoclasts, it can be
suggested that the SrCPC degradation process is not impaired by a
potential anti-osteoclastic effect of the released Sr shown by
reduction of RANKL expression in immunohistochemistry.
Biomaterials should be investigated in a clinically relevant
model targeting their intended clinical use. Although most calcium
phosphate cements are applied in fracture defects in patients,
in vivo testing of these materials is mainly done in simple drill hole
defects that does not represent clinically reality. The strength of theused animal model [14] is that it allows investigation of bio-
materials in a clinically relevant situation. It exposes the materials
to a fracture defect in the metaphyseal region of long bone rats.
Internal ﬁxation with the T-shaped plate on the distal femur also
corresponds to the human situation. Ovariectomy and special diet
was shown to lead to a signiﬁcant reduction of bone mineral den-
sity compared to sham animals [14,17,18]. The materials are chal-
lenged with typical defect fracture healing processes for bone
consolidation in this model under systemically impaired bone
conditions. Compared to the previous study [14], we used a 4 mm
fracture defect which could be shown to fulﬁll all requirements for
a critical size defect in the empty defect control group as it did not
show any bony consolidation after 6 weeks in this study. Therefore,
the 4 mm fracture defect is a good model to study potential bone
enhancement effects of biomaterials. Plate breakages in this model
could be regarded as a drawback. However, even this fact links
the model to clinical reality as plate breakages in the human situ-
ation are a typical sign for implant failure in case of impaired
bone healing such as delayed or non-unions. Although, there was a
non-statistically signiﬁcant difference in plate breakages, with a
p-value of p ¼ 0.06 that there was a strong trend with fewer
implant failure in the SrCPC compared to the CPC suggesting better
bone healing for this parameter.
5. Conclusion
Both CPC and SrCPC revealed a statistically signiﬁcantly
enhanced new bone formation compared to the empty defect in a
critical size defect in the metaphyseal area of the distal femur in
ovariectomized rats. It could be shown that the SrCPC treated an-
imals exhibited a statistically signiﬁcant higher new bone forma-
tion both at the biomaterialebone interface and in the entire
fracture defect area compared to CPC. TOF-SIMS analysis could
detect high count rates Sr from the SrCPC in the interface region
and up to a distance of 6 mm to the implant which was not the case
for CPC. This suggests that the enhanced new bone formation is
attributable to local release from the SrCPC.
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